Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab Post Trial Access in Multiple Myeloma
NCT06057402Phase 4Recruiting
- Sponsor
- Pfizer
- Start
- Oct 2023
- Primary completion
- Feb 2032
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 4, open-label, single-arm trial of elranatamab in multiple myeloma (MM), sponsored by Pfizer. Primary endpoints: Incidence of nonserious adverse events (AEs) leading to permanent discontinuation and Incidence of serious adverse events (SAEs). Started Oct 2023; status: recruiting.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06057402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06057402.